vs
Amphastar Pharmaceuticals, Inc.（AMPH）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是弗雷斯特研究公司的1.8倍（$183.1M vs $101.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -33.5%，领先46.9%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -6.5%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-4.3M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 0.5%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
AMPH vs FORR — 直观对比
营收规模更大
AMPH
是对方的1.8倍
$101.1M
营收增速更快
AMPH
高出4.6%
-6.5%
净利率更高
AMPH
高出46.9%
-33.5%
自由现金流更多
AMPH
多$28.9M
$-4.3M
两年增速更快
AMPH
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $101.1M |
| 净利润 | $24.4M | $-33.9M |
| 毛利率 | 46.8% | 56.7% |
| 营业利润率 | 19.4% | -36.6% |
| 净利率 | 13.3% | -33.5% |
| 营收同比 | -1.8% | -6.5% |
| 净利润同比 | -35.7% | -7941.4% |
| 每股收益（稀释后） | $0.51 | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHFORR
| Q4 25 | $183.1M | $101.1M | ||
| Q3 25 | $191.8M | $94.3M | ||
| Q2 25 | $174.4M | $111.7M | ||
| Q1 25 | $170.5M | $89.9M | ||
| Q4 24 | $186.5M | $108.0M | ||
| Q3 24 | $191.2M | $102.5M | ||
| Q2 24 | $182.4M | $121.8M | ||
| Q1 24 | $171.8M | $100.1M |
净利润AMPHFORR
| Q4 25 | $24.4M | $-33.9M | ||
| Q3 25 | $17.4M | $-2.1M | ||
| Q2 25 | $31.0M | $3.9M | ||
| Q1 25 | $25.3M | $-87.3M | ||
| Q4 24 | $38.0M | $432.0K | ||
| Q3 24 | $40.4M | $-5.8M | ||
| Q2 24 | $37.9M | $6.3M | ||
| Q1 24 | $43.2M | $-6.7M |
毛利率AMPHFORR
| Q4 25 | 46.8% | 56.7% | ||
| Q3 25 | 51.4% | 60.0% | ||
| Q2 25 | 49.6% | 55.5% | ||
| Q1 25 | 50.0% | 55.9% | ||
| Q4 24 | 46.5% | 58.8% | ||
| Q3 24 | 53.3% | 60.5% | ||
| Q2 24 | 52.2% | 57.3% | ||
| Q1 24 | 52.4% | 54.9% |
营业利润率AMPHFORR
| Q4 25 | 19.4% | -36.6% | ||
| Q3 25 | 13.2% | 4.7% | ||
| Q2 25 | 24.2% | 6.2% | ||
| Q1 25 | 21.9% | -97.5% | ||
| Q4 24 | 24.2% | -0.5% | ||
| Q3 24 | 29.8% | -0.7% | ||
| Q2 24 | 30.3% | 9.3% | ||
| Q1 24 | 27.9% | -9.3% |
净利率AMPHFORR
| Q4 25 | 13.3% | -33.5% | ||
| Q3 25 | 9.0% | -2.3% | ||
| Q2 25 | 17.8% | 3.5% | ||
| Q1 25 | 14.8% | -97.1% | ||
| Q4 24 | 20.4% | 0.4% | ||
| Q3 24 | 21.1% | -5.7% | ||
| Q2 24 | 20.8% | 5.2% | ||
| Q1 24 | 25.1% | -6.7% |
每股收益（稀释后）AMPHFORR
| Q4 25 | $0.51 | $-1.75 | ||
| Q3 25 | $0.37 | $-0.11 | ||
| Q2 25 | $0.64 | $0.20 | ||
| Q1 25 | $0.51 | $-4.62 | ||
| Q4 24 | $0.74 | $0.02 | ||
| Q3 24 | $0.78 | $-0.30 | ||
| Q2 24 | $0.73 | $0.33 | ||
| Q1 24 | $0.81 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $63.3M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $126.5M |
| 总资产 | $1.6B | $404.0M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHFORR
| Q4 25 | $282.8M | $63.3M | ||
| Q3 25 | $276.2M | $65.1M | ||
| Q2 25 | $231.8M | $67.8M | ||
| Q1 25 | $236.9M | $75.6M | ||
| Q4 24 | $221.6M | $56.1M | ||
| Q3 24 | $250.5M | $62.8M | ||
| Q2 24 | $217.8M | $58.9M | ||
| Q1 24 | $289.6M | $61.4M |
总债务AMPHFORR
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHFORR
| Q4 25 | $788.8M | $126.5M | ||
| Q3 25 | $776.7M | $157.7M | ||
| Q2 25 | $757.5M | $159.5M | ||
| Q1 25 | $751.3M | $147.4M | ||
| Q4 24 | $732.3M | $229.5M | ||
| Q3 24 | $727.7M | $234.3M | ||
| Q2 24 | $713.3M | $237.1M | ||
| Q1 24 | $672.4M | $230.9M |
总资产AMPHFORR
| Q4 25 | $1.6B | $404.0M | ||
| Q3 25 | $1.7B | $414.2M | ||
| Q2 25 | $1.6B | $436.0M | ||
| Q1 25 | $1.6B | $439.8M | ||
| Q4 24 | $1.6B | $503.9M | ||
| Q3 24 | $1.5B | $505.3M | ||
| Q2 24 | $1.5B | $524.2M | ||
| Q1 24 | $1.6B | $555.7M |
负债/权益比AMPHFORR
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-4.3M |
| 自由现金流率自由现金流/营收 | 13.4% | -4.2% |
| 资本支出强度资本支出/营收 | 4.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $18.1M |
8季度趋势，按日历期对齐
经营现金流AMPHFORR
| Q4 25 | $32.9M | $-3.2M | ||
| Q3 25 | $52.6M | $1.2M | ||
| Q2 25 | $35.6M | $-3.6M | ||
| Q1 25 | $35.1M | $26.7M | ||
| Q4 24 | $29.0M | $-1.8M | ||
| Q3 24 | $60.0M | $264.0K | ||
| Q2 24 | $69.1M | $-2.9M | ||
| Q1 24 | $55.3M | $611.0K |
自由现金流AMPHFORR
| Q4 25 | $24.6M | $-4.3M | ||
| Q3 25 | $47.2M | $524.0K | ||
| Q2 25 | $25.0M | $-4.2M | ||
| Q1 25 | $24.4M | $26.1M | ||
| Q4 24 | $16.6M | $-2.5M | ||
| Q3 24 | $46.2M | $-223.0K | ||
| Q2 24 | $63.1M | $-3.7M | ||
| Q1 24 | $46.5M | $-815.0K |
自由现金流率AMPHFORR
| Q4 25 | 13.4% | -4.2% | ||
| Q3 25 | 24.6% | 0.6% | ||
| Q2 25 | 14.3% | -3.8% | ||
| Q1 25 | 14.3% | 29.0% | ||
| Q4 24 | 8.9% | -2.3% | ||
| Q3 24 | 24.1% | -0.2% | ||
| Q2 24 | 34.6% | -3.1% | ||
| Q1 24 | 27.1% | -0.8% |
资本支出强度AMPHFORR
| Q4 25 | 4.5% | 1.1% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.5% | ||
| Q1 25 | 6.3% | 0.7% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 5.1% | 1.4% |
现金转化率AMPHFORR
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | -0.93× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | -4.24× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | -0.46× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
